LOINC Home

{component}   LP432695-7

Laboratory   LP29693-6

Chemistry and Chemistry - challenge   LP343631-0

Chemistry - non-challenge   LP7786-9

Chemistry Panels   LP7834-7

Fatty acid oxidation newborn screen panel   LP97000-1

Fatty acid oxidation newborn screen panel | DBS | Chemistry Panels   LP386909-8

Fatty acid oxidation newborn screen panel   57084-6

LOINC Code


LOINC code57084-6
nameFatty acid oxidation newborn screen panel
descriptionNewborn screening dried blood spot analysis by tandem mass spectrometry (MS/MS) requires pre-processing the specimen with one of two alternative reagent methods referred to as derivatized and non-derivatized (or underivatized) methods. The methods are similar and nearly all analytes and ratios are identical with the limited number of exceptions noted in the description of the LOINC codes. Some labs choose to use the non-derivatized method because it may be faster or less expensive for their operations. There are no analytes which would be interpreted differently based on the method used to process the specimen so there is no need for different LOINC codes for the same compounds based on the reagents. In a few cases, a different LOINC code is used for the derivatized or non-derivatized tandem mass spectrometry (MS/MS) method because based on the reagents used in processing, different analytes are measured or different sets of analytes become isobaric, which means that they cannot be distinguished on the MS/MS because they have the same molecular weight after reagent processing.
statusACTIVE

Fully-Specified Name

componentFatty acid oxidation newborn screen panel
property-
timePt  =  Point in time:  To identify measures at a point in time. This is a synonym for “spot” or “random” as applied to urine measurements.
systemBld.dot  =  Blood filter paper
scale-
method

Additional Names

short nameFA oxidation NB scn pnl DBS

Basic Attributes

classPANEL.CHEM
type1  Laboratory
order vs. observationOrder

Panel Components

46736-5Fatty acid oxidation defects newborn screen interpretation
57792-4Fatty acid oxidation conditions suspected [Identifier] in DBS
57709-8Fatty acid oxidation defects newborn screening comment-discussion
38481-8Carnitine free (C0) [Moles/volume] in DBS
53233-3Carnitine free (C0)/Palmitoylcarnitine (C16) [Molar ratio] in DBS
53234-1Carnitine free (C0)/Stearoylcarnitine (C18) [Molar ratio] in DBS
53235-8Carnitine free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18) [Molar ratio] in DBS
53236-6Carnitine.free (C0)+Acetylcarnitine (C2)+Propionylcarnitine (C3)+Palmitoylcarnitine (C16)+Oleoylcarnitine (C18:1)+Stearoylcarnitine (C18)/Citrulline [Molar ratio] in DBS
75211-3Propionylcarnitine (C3)+Palmitoylcarnitine (C16) [Moles/volume] in DBS
75212-1Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in DBS
54462-7Malonylcarnitine (C3-DC) [Moles/volume] in DBS
75213-9Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)/Decanoylcarnitine (C10) [Molar ratio] in DBS
50157-7Acetylcarnitine (C2) [Moles/volume] in DBS
53166-5Butyrylcarnitine+Isobutyrylcarnitine (C4) [Moles/volume] in DBS
53167-3Butyrylcarnitine+Isobutyrylcarnitine (C4)/Acetylcarnitine (C2) [Molar ratio] in DBS
53168-1Butyrylcarnitine+Isobutyrylcarnitine (C4)/Propionylcarnitine (C3) [Molar ratio] in DBS
53169-9Butyrylcarnitine+Isobutyrylcarnitine (C4)/Octanoylcarnitine (C8) [Molar ratio] in DBS
50102-33-Hydroxybutyrylcarnitine (C4-OH) [Moles/volume] in DBS
45211-0Hexanoylcarnitine (C6) [Moles/volume] in DBS
53173-13-Hydroxyhexanoylcarnitine (C6-OH) [Moles/volume] in DBS
45207-8Glutarylcarnitine (C5-DC) [Moles/volume] in DBS
53174-9Octenoylcarnitine (C8:1) [Moles/volume] in DBS
53175-6Octanoylcarnitine (C8) [Moles/volume] in DBS
53176-4Octanoylcarnitine (C8)/Acetylcarnitine (C2) [Molar ratio] in DBS
53177-2Octanoylcarnitine (C8)/Decanoylcarnitine (C10) [Molar ratio] in DBS
53178-03-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC) [Moles/volume] in DBS
53402-43-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Butyrylcarnitine+Isobutyrylcarnitine (C4) [Molar ratio] in DBS
53179-83-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in DBS
53180-6Decadienoylcarnitine (C10:2) [Moles/volume] in DBS
45198-9Decenoylcarnitine (C10:1) [Moles/volume] in DBS
45197-1Decanoylcarnitine (C10) [Moles/volume] in DBS
53182-23-Hydroxydecenoylcarnitine (C10:1-OH) [Moles/volume] in DBS
53183-0Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH) [Moles/volume] in DBS
53403-2Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Butyrylcarnitine+Isobutyrylcarnitine (C4) [Molar ratio] in DBS
53184-8Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in DBS
53185-5Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Octanoylcarnitine (C8) [Molar ratio] in DBS
53186-3Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS
45200-3Dodecenoylcarnitine (C12:1) [Moles/volume] in DBS
45199-7Dodecanoylcarnitine (C12) [Moles/volume] in DBS
53188-93-Hydroxydodecenoylcarnitine (C12:1-OH) [Moles/volume] in DBS
53189-73-Hydroxydodecanoylcarnitine (C12-OH) [Moles/volume] in DBS
53190-5Tetradecadienoylcarnitine (C14:2) [Moles/volume] in DBS
53191-3Tetradecenoylcarnitine (C14:1) [Moles/volume] in DBS
53192-1Tetradecanoylcarnitine (C14) [Moles/volume] in DBS
53193-9Tetradecenoylcarnitine (C14:1)/Acetylcarnitine (C2) [Molar ratio] in DBS
53194-7Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1) [Molar ratio] in DBS
53195-4Tetradecenoylcarnitine (C14:1)/Palmitoylcarnitine (C16) [Molar ratio] in DBS
70159-9Tetradecenoylcarnitine (C14:1)/Tetradecanoylcarnitine (C14) [Molar ratio] in DBS
53196-23-Hydroxytetradecadienoylcarnitine (C14:2-OH) [Moles/volume] in DBS
53197-03-Hydroxytetradecenoylcarnitine (C14:1-OH) [Moles/volume] in DBS
50281-53-Hydroxytetradecanoylcarnitine (C14-OH) [Moles/volume] in DBS
53198-8Palmitoleylcarnitine (C16:1) [Moles/volume] in DBS
53199-6Palmitoylcarnitine (C16) [Moles/volume] in DBS
50121-33-Hydroxypalmitoleylcarnitine (C16:1-OH) [Moles/volume] in DBS
50125-43-Hydroxypalmitoylcarnitine (C16-OH) [Moles/volume] in DBS
53201-03-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS
45217-7Linoleoylcarnitine (C18:2) [Moles/volume] in DBS
53202-8Oleoylcarnitine (C18:1) [Moles/volume] in DBS
53241-6Stearoylcarnitine (C18) [Moles/volume] in DBS
53400-8Stearoylcarnitine (C18)/Propionylcarnitine (C3) [Molar ratio] in DBS
50109-83-Hydroxylinoleoylcarnitine (C18:2-OH) [Moles/volume] in DBS
50113-03-Hydroxyoleoylcarnitine (C18:1-OH) [Moles/volume] in DBS
50132-03-Hydroxystearoylcarnitine (C18-OH) [Moles/volume] in DBS
53836-3ABCD1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method

Associated Observations

LOINC codes that represent optional associated observation(s) for a clinical observation or laboratory test. A LOINC term may represent a single associated observation or panel containing several associated observations.

Member of these Panels

58092-8Acylcarnitine newborn screen panel

History/Usage

test rank17172 of 2000 most commonly performed tests by labs in USA
first released
last updated2.77
last change typePANEL  - addition or removal of child elements or change in the conditionality of child elements in the panel or in sub-panels contained by the panel.

Related Names

Acd
Acids
Blood
Chemistry
DBS
Dried blood spot
FA Oxidation
FA oxidation NB scn pnl
FAO
Filter paper
FP
Gyn
Gynecology
New born
 OB
ObGyn
Obstetrics
Pan
PANEL.CHEMISTRY
Panl
Pnl
Point in time
Random
Scn
Scr
Scrn
WB
Whole blood

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.